[go: up one dir, main page]

HUP0104268A2 - Hosszan tartó hatóanyag-kibocsátású fluvasztatin-tartalmú gyógyászati készítmény - Google Patents

Hosszan tartó hatóanyag-kibocsátású fluvasztatin-tartalmú gyógyászati készítmény

Info

Publication number
HUP0104268A2
HUP0104268A2 HU0104268A HUP0104268A HUP0104268A2 HU P0104268 A2 HUP0104268 A2 HU P0104268A2 HU 0104268 A HU0104268 A HU 0104268A HU P0104268 A HUP0104268 A HU P0104268A HU P0104268 A2 HUP0104268 A2 HU P0104268A2
Authority
HU
Hungary
Prior art keywords
pharmaceutical composition
molecular weight
composition containing
sustained release
release pharmaceutical
Prior art date
Application number
HU0104268A
Other languages
English (en)
Inventor
Arun P. Patel
Roy T. Sandry
Rajen Shah
Original Assignee
Novartis Ag.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22627919&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUP0104268(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag. filed Critical Novartis Ag.
Publication of HUP0104268A2 publication Critical patent/HUP0104268A2/hu
Publication of HUP0104268A3 publication Critical patent/HUP0104268A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

A jelen tal lm ny szil rd, hosszan tartó hatóanyag-kibocs t sú, or lisdózisform ra hozott gyógy szati készítményre vonatkozik, melyfluorasztatin gyógy szatilag hat sos mennyiségét tartalmazza, tov bbhidroxi-propil-metil-cellulózt és valamely nem ionos, hidrofilpolimert tartalmaz a k"vetkezők k"zül v lasztva: hidroxi-etil-cellulóz90,000-1,300,000 tlagos molekulat"meggel, hidroxi-propil-cellulóz370,000-1,500,000 tlagos molekulat"meggel, és poli(etilén-oxid)100,000- 500,000 tlagos molekulat"meggel. Ó
HU0104268A 1998-10-14 1999-10-12 Sustained release pharmaceutical composition containing fluvastatin HUP0104268A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17249198A 1998-10-14 1998-10-14
PCT/EP1999/007627 WO2000021525A2 (en) 1998-10-14 1999-10-12 Sustained release pharmaceutical composition and method of releasing pharmaceutically active agent

Publications (2)

Publication Number Publication Date
HUP0104268A2 true HUP0104268A2 (hu) 2002-04-29
HUP0104268A3 HUP0104268A3 (en) 2002-06-28

Family

ID=22627919

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0104268A HUP0104268A3 (en) 1998-10-14 1999-10-12 Sustained release pharmaceutical composition containing fluvastatin

Country Status (30)

Country Link
EP (1) EP1121116B1 (hu)
JP (2) JP2002527388A (hu)
KR (1) KR100517090B1 (hu)
CN (1) CN1196481C (hu)
AR (2) AR020780A1 (hu)
AT (1) ATE382345T1 (hu)
AU (1) AU765475B2 (hu)
BR (1) BR9911648A (hu)
CA (1) CA2346868C (hu)
CO (1) CO5140079A1 (hu)
CY (1) CY1107874T1 (hu)
DE (1) DE69937891T2 (hu)
DK (1) DK1121116T3 (hu)
ES (1) ES2297936T3 (hu)
HK (1) HK1040920B (hu)
HU (1) HUP0104268A3 (hu)
ID (1) ID29350A (hu)
IL (2) IL142375A0 (hu)
MY (1) MY121105A (hu)
NO (1) NO327285B1 (hu)
NZ (1) NZ511010A (hu)
PE (1) PE20001110A1 (hu)
PL (1) PL198850B1 (hu)
PT (1) PT1121116E (hu)
RU (1) RU2259826C2 (hu)
SK (2) SK286596B6 (hu)
TR (1) TR200101088T2 (hu)
TW (1) TW577738B (hu)
WO (1) WO2000021525A2 (hu)
ZA (1) ZA200103001B (hu)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6569461B1 (en) 1999-03-08 2003-05-27 Merck & Co., Inc. Dihydroxy open-acid and salts of HMG-CoA reductase inhibitors
US6242003B1 (en) * 2000-04-13 2001-06-05 Novartis Ag Organic compounds
WO2001093859A1 (en) 2000-06-09 2001-12-13 Lek Pharmaceuticals D.D. Stable pharmaceutical product and formulation
AU2002223572B2 (en) * 2000-09-29 2005-09-08 Abbvie B.V. Ion-strength independent sustained release pharmaceutical formulation
US20060127474A1 (en) 2001-04-11 2006-06-15 Oskar Kalb Pharmaceutical compositions comprising fluvastatin
EP1537880A4 (en) * 2002-09-11 2009-07-01 Takeda Pharmaceutical Sustained release preparation
US20070042143A1 (en) * 2003-04-23 2007-02-22 Ferring B.V. Sachet for a pharmaceutical composition
US8987322B2 (en) 2003-11-04 2015-03-24 Circ Pharma Research And Development Limited Pharmaceutical formulations for carrier-mediated transport statins and uses thereof
DE102004062475A1 (de) * 2004-12-24 2006-07-06 Bayer Healthcare Ag Feste, oral applizierbare pharmazeutische Darreichungsformen mit modifizierter Freisetzung
KR100582347B1 (ko) * 2004-12-30 2006-05-22 한미약품 주식회사 3-하이드록시-3-메틸글루타릴 조효소 ａ 환원효소 억제제및 고혈압 치료제의 복합제제 및 그의 제조방법
EP1940391A4 (en) * 2005-08-05 2010-01-20 Orbus Pharma Inc STABILIZED PHARMACEUTICAL COMPOSITIONS WITH EXTENDED RELEASE WITH AN HMG COA REDUCTASE INHIBITOR
CN101426478A (zh) * 2006-02-24 2009-05-06 特瓦制药工业有限公司 氟伐他汀钠药物组合物
RU2356532C2 (ru) * 2007-06-01 2009-05-27 Открытое Акционерное Общество "Отечественные Лекарства" Фармацевтическая композиция проксодолола с контролируемым высвобождением
CN102805739B (zh) * 2012-04-10 2013-08-14 宋芸 氟伐他汀钠缓释包衣滴丸及其制备方法
CA2897313A1 (en) * 2013-01-09 2014-07-17 Edgemont Pharmaceuticals Llc Controlled release formulations of lorazepam
CN106344535B (zh) * 2016-08-29 2019-09-20 济南康和医药科技有限公司 一种氟伐他汀钠微孔渗透泵控释片及其制备方法
SG11202005016SA (en) 2017-12-05 2020-06-29 Sunovion Pharmaceuticals Inc Nonracemic mixtures and uses thereof
EP3720435B1 (en) 2017-12-05 2024-03-06 Sunovion Pharmaceuticals Inc. Crystal forms and production methods thereof
CN112955139A (zh) 2018-09-25 2021-06-11 庞塞迪利昂健康特定活动公司 用于制备α-酮戊二酸钙的方法
CN114401717A (zh) 2019-06-04 2022-04-26 赛诺维信制药公司 修饰释放配制品及其用途
BR112021024952A2 (pt) * 2019-06-10 2022-02-15 Ponce De Leon Health Designated Activity Company Composições de liberação sustentada de alfa-cetoglutarato

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4915954A (en) * 1987-09-03 1990-04-10 Alza Corporation Dosage form for delivering a drug at two different rates
CA2045428A1 (en) * 1990-06-26 1991-12-27 Alfred W. Alberts Method for enhancing the lowering of plasma cholesterol levels
GB9523752D0 (en) * 1995-11-21 1996-01-24 Pfizer Ltd Pharmaceutical formulations
ATE228354T1 (de) * 1995-12-22 2002-12-15 Kowa Co Pharmazeutische zusammensetzung stabilisiert mit einem basischen medium
SE9603667D0 (sv) * 1996-10-08 1996-10-08 Astra Ab Pharmaceutical compositions

Also Published As

Publication number Publication date
NZ511010A (en) 2003-10-31
DE69937891D1 (de) 2008-02-14
HUP0104268A3 (en) 2002-06-28
NO20011695D0 (no) 2001-04-04
WO2000021525A3 (en) 2000-08-10
SK286595B6 (sk) 2009-01-07
ID29350A (id) 2001-08-23
CO5140079A1 (es) 2002-03-22
AR020780A1 (es) 2002-05-29
SK5092001A3 (en) 2001-09-11
SK286596B6 (sk) 2009-01-07
CN1196481C (zh) 2005-04-13
IL142375A (en) 2012-01-31
EP1121116A2 (en) 2001-08-08
CA2346868C (en) 2008-09-09
BR9911648A (pt) 2001-03-20
NO20011695L (no) 2001-05-30
MY121105A (en) 2005-12-30
HK1040920A1 (en) 2002-06-28
PL348109A1 (en) 2002-05-06
JP2002527388A (ja) 2002-08-27
PE20001110A1 (es) 2000-11-01
AR069281A2 (es) 2010-01-13
RU2259826C2 (ru) 2005-09-10
DE69937891T2 (de) 2008-12-11
PL198850B1 (pl) 2008-07-31
ZA200103001B (en) 2002-07-11
TW577738B (en) 2004-03-01
EP1121116B1 (en) 2008-01-02
JP2006298945A (ja) 2006-11-02
CY1107874T1 (el) 2013-06-19
CA2346868A1 (en) 2000-04-20
WO2000021525A2 (en) 2000-04-20
AU6090999A (en) 2000-05-01
NO327285B1 (no) 2009-06-02
CN1328454A (zh) 2001-12-26
ATE382345T1 (de) 2008-01-15
PT1121116E (pt) 2008-03-12
ES2297936T3 (es) 2008-05-01
TR200101088T2 (tr) 2001-10-22
KR20010080156A (ko) 2001-08-22
IL142375A0 (en) 2002-03-10
AU765475B2 (en) 2003-09-18
HK1040920B (zh) 2005-07-29
DK1121116T3 (da) 2008-05-13
JP4938383B2 (ja) 2012-05-23
KR100517090B1 (ko) 2005-09-27

Similar Documents

Publication Publication Date Title
HUP0104268A2 (hu) Hosszan tartó hatóanyag-kibocsátású fluvasztatin-tartalmú gyógyászati készítmény
CN1929819B (zh) 递送活性剂的快速溶解膜
US5955097A (en) Pharmaceutical preparation applicable to mucosal surfaces and body tissues
CA2371940A1 (en) Pregelatinized starch in a controlled release formulation
HUP0201877A2 (hu) Hal zselatint tartalmazó, gyorsan diszpergálódó dózis formák
EP0966966A3 (en) Nefazodone dosage form
EP2601939A3 (en) Hydrogel compositions with an erodible backing member
MXPA04007980A (es) Preparado farmaceutico de sabor enmascarado en forma de pelicula o de oblea.
HUP0101598A2 (hu) Aszpartil proteáz inhibitorok prodrugjai és ezeket tartalmazó gyógyszerkészítmények
CA2401569A1 (en) Low dose entecavir formulation and use
AU2001296865A1 (en) (5-(2-hydroxy-4-chlorobenzoyl) aminovaleric acid and salts thereof and compositions containing the same for delivering active agents
CA2377174A1 (en) Oral administration forms for administering a fixed tramadol and diclofenac combination
KR102272442B1 (ko) 계면활성제 또는 폴리알콜을 포함하지 않은 즉각적 습윤성의 경구용 필름 제형
US20210259952A1 (en) Oral compositions and mucoadhesive thin films formed therefrom
ATE375789T1 (de) Orales abgabesystem mit einem antibakteriellen und einem entzündungshemmenden mittel
WO1999047172A3 (en) Oral pharmaceutical compositions to be taken without liquids, which contain inclusion complexes
SE9902937D0 (sv) Pharmaceutical compositions
JP2000063268A (ja) 口腔粘膜付着型徐放性錠剤及び歯周疾患治療剤
WO2005107702A3 (en) Sustained release, mucoadhesive vaginal pharmaceutical compositions
SE9902936D0 (sv) Pharmaceutical compositions
JP2009149540A (ja) 歯磨組成物
WO2004000253A1 (en) Improved pharmaceutical dental formulations
Cerrato Troglitazone may lessen effect of OCs.
MY128958A (en) New oral formulation for 5-ht4 agonists or antagonists.

Legal Events

Date Code Title Description
FC4A Lapse of provisional application due to refusal